Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Sonneveld, Pieter; Avet‐Loiseau, Hervé; Lonial, Sagar; Z. Usmani, Saad; S. Siegel, David; C. Anderson, Kenneth; Joo Chng, Wee; Moreau, Philippe; Attal, Michel; A. Kyle, Robert; Caers, Jo; Hillengaß, Jens; F. San Miguel, Jesús; W.C.J. van de Donk, Niels; Einsele, Hermann; Bladé, Joan; G.M. Durie, Brian; Goldschmidt, Hartmut; Mateos, María‐Victoria; Palumbo, Antonio; Z. Orlowski, Robert

doi:10.1182/blood-2016-01-631200

Public

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Published in Blood • Mar 22, 2016

Authors:

Pieter Sonneveld

Hervé Avet‐Loiseau

Sagar Lonial

Abstract

The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The progno...

Subject

Lenalidomide

Pomalidomide

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!